Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$6.7 - $24.21 $1.1 Million - $3.97 Million
-164,152 Reduced 87.16%
24,190 $582,000
Q4 2022

Feb 09, 2023

BUY
$4.52 - $10.57 $197,338 - $461,475
43,659 Added 30.18%
188,342 $1.99 Million
Q3 2022

Nov 09, 2022

BUY
$3.43 - $5.62 $240,449 - $393,973
70,102 Added 93.99%
144,683 $651,000
Q2 2022

Aug 11, 2022

BUY
$3.65 - $7.3 $272,220 - $544,441
74,581 New
74,581 $298,000
Q1 2022

May 12, 2022

SELL
$3.4 - $7.88 $222,638 - $515,998
-65,482 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$5.59 - $7.39 $101,821 - $134,608
-18,215 Reduced 21.76%
65,482 $368,000
Q3 2021

Nov 12, 2021

SELL
$5.66 - $8.33 $421,986 - $621,051
-74,556 Reduced 47.11%
83,697 $536,000
Q2 2021

Aug 10, 2021

BUY
$6.71 - $11.04 $1.06 Million - $1.75 Million
158,253 New
158,253 $1.33 Million
Q1 2021

May 12, 2021

SELL
$10.12 - $19.45 $543,869 - $1.05 Million
-53,742 Closed
0 $0
Q4 2020

Feb 10, 2021

SELL
$11.79 - $18.94 $194,924 - $313,135
-16,533 Reduced 23.53%
53,742 $910,000
Q3 2020

Nov 12, 2020

BUY
$10.34 - $15.2 $12,397 - $18,224
1,199 Added 1.74%
70,275 $902,000
Q2 2020

Aug 13, 2020

BUY
$7.81 - $17.0 $194,859 - $424,150
24,950 Added 56.54%
69,076 $975,000
Q1 2020

May 13, 2020

BUY
$5.42 - $17.75 $201,580 - $660,158
37,192 Added 536.37%
44,126 $406,000
Q4 2019

Feb 10, 2020

BUY
$5.84 - $14.9 $17,566 - $44,819
3,008 Added 76.62%
6,934 $103,000
Q3 2019

Nov 12, 2019

BUY
$6.83 - $13.0 $26,814 - $51,038
3,926 New
3,926 $27,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.